Start of rolling review for adapted Spikevax COVID-19 vaccine

Moderna

17 June 2022 - EMA has started a rolling review for a version of Spikevax adapted to provide better protection against specific variants of SARS-CoV-2, the virus that causes COVID-19.

The review concerns a bivalent vaccine. This means it will target two strains of SARS-CoV-2, in this case the original strain and the Omicron variant of concern.

Read EMA press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Europe , Vaccine , Dossier , COVID-19